Bicara Therapeutics, Inc. (BCAX)
22.02
-0.62
(-2.74%)
USD |
NASDAQ |
Sep 21, 16:00
22.02
0.00 (0.00%)
After-Hours: 20:00
Bicara Therapeutics Debt to Equity Ratio : 0.0025 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0025 |
| March 31, 2026 | 0.0028 |
| December 31, 2025 | 0.0043 |
| September 30, 2025 | 0.0049 |
| June 30, 2025 | 0.0051 |
| March 31, 2025 | 0.0013 |
| Date | Value |
|---|---|
| December 31, 2024 | 0.0015 |
| September 30, 2024 | 0.0009 |
| June 30, 2024 | 0.0027 |
| March 31, 2024 | |
| December 31, 2023 | 0.003 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 512.24M |
| Total Liabilities (Quarterly) | 43.48M |
| Shareholders Equity (Quarterly) | 468.77M |
| Current Ratio | 11.59 |
| Net Debt Paydown Yield | -0.01% |